Objective: Photobiomodulation (PBM) is a noninvasive therapy utilising low-level light energy to stimulate cellular processes, modulate inflammatory pathways, enhance mitochondrial activity, promote tissue regeneration. With growing interest in PBM as a potential treatment modality, this review synthesises current evidence and highlights challenges of implementing PBM across various ophthalmic conditions.

Results: Current ophthalmic applications of PBM can be categorised into established and exploratory therapies, differentiated primarily by the attainment of regulatory approval. Established applications of PBM include the treatment of dry eye disease and nonexudative age-related macular degeneration, while the use of PBM is still largely exploratory in conditions such as diabetic macular oedema and retinopathy of prematurity. Regardless of the level of regulatory authorisation, the application of PBM in each ophthalmic condition presents with distinct challenges requiring further research for comprehensive validation.

Conclusions: While PBM holds promise as a novel therapeutic option, its long-term efficacy and safety remains to be fully established. Standardised treatment guidelines and larger randomised controlled trials are essential to optimise its use in future clinical practice.